Literature DB >> 17911453

Targeting vascular adhesion protein-1 to treat autoimmune and inflammatory diseases.

David J Smith1, Petri J Vainio.   

Abstract

The development of new, safe, and effective anti-inflammatory drugs represents a major challenge for the pharmaceutical industry, as well as a significant opportunity. The increasing prevalence of chronic inflammatory and autoimmune diseases associated with an aging population has led to an intense effort to discover new anti-inflammatory drug targets and drugs acting against them. This review highlights the recent progress made in developing therapies directed against an endothelial cell adhesion molecule called vascular adhesion protein (VAP)-1 for the treatment of chronic inflammatory disease as well as highlighting other therapeutic opportunities offered by this vascular target.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17911453     DOI： 10.1196/annals.1423.040

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  10 in total

1.  Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization.

Authors:  Anna Enzsöly; Petra Dunkel; Zsuzsa Récsán; Hajnalka Gyorffy; Jeanette Tóth; Gábor Marics; Zoltán Bori; Miklós Tóth; Romána Zelkó; Maria Luisa Di Paolo; Péter Mátyus; János Németh
Journal:  J Neural Transm (Vienna)       Date:  2011-02-18       Impact factor: 3.575

2.  The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function.

Authors:  Thomas Noonan; Susan Lukas; Gregory W Peet; Josephine Pelletier; Mark Panzenbeck; Adedayo Hanidu; Suzanne Mazurek; Ruby Wasti; Irina Rybina; Teresa Roma; Anthony Kronkaitis; Alycia Shoultz; Donald Souza; Huiping Jiang; Gerald Nabozny; Louise Kelly Modis
Journal:  Am J Clin Exp Immunol       Date:  2013-06-15

3.  A new crystal form of human vascular adhesion protein 1.

Authors:  Karin Ernberg; Aaron P McGrath; Thomas S Peat; Timothy E Adams; Xiaowen Xiao; Tam Pham; Janet Newman; Ian A McDonald; Charles A Collyer; J Mitchell Guss
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-11-16

Review 4.  Vascular adhesion protein-1 and microvascular diabetic complications.

Authors:  Alok D Singh; Yogesh A Kulkarni
Journal:  Pharmacol Rep       Date:  2022-01-10       Impact factor: 3.024

5.  Leukocyte adhesion molecules in diabetic retinopathy.

Authors:  Kousuke Noda; Shintaro Nakao; Susumu Ishida; Tatsuro Ishibashi
Journal:  J Ophthalmol       Date:  2011-11-02       Impact factor: 1.909

Review 6.  Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy.

Authors:  David S Boyer; Joerg F Rippmann; Michael S Ehrlich; Remko A Bakker; Victor Chong; Quan Dong Nguyen
Journal:  Int J Retina Vitreous       Date:  2021-04-12

7.  Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.

Authors:  Tomoyoshi Inoue; Thomas Byrne; Mitsuko Inoue; Madeline E Tait; Patrick Wall; Annabel Wang; Michael R Dermyer; Hanane Laklai; Joseph J Binder; Clare Lees; Robert Hollingsworth; Liliana Maruri-Avidal; David H Kirn; Donald M McDonald
Journal:  Mol Cancer Ther       Date:  2021-05-27       Impact factor: 6.261

8.  Dietary Phenolic Compounds Interfere with the Fate of Hydrogen Peroxide in Human Adipose Tissue but Do Not Directly Inhibit Primary Amine Oxidase Activity.

Authors:  Christian Carpéné; Mounia Hasnaoui; Balázs Balogh; Peter Matyus; Alfredo Fernández-Quintela; Víctor Rodríguez; Josep Mercader; Maria P Portillo
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

Review 9.  The three Rs: Recruitment, Retention and Residence of leukocytes in the liver.

Authors:  Hayley A McNamara; Ian A Cockburn
Journal:  Clin Transl Immunology       Date:  2016-12-30

Review 10.  SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.

Authors:  Mercedes Unzeta; Mar Hernàndez-Guillamon; Ping Sun; Montse Solé
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.